Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sentinel lymph node detection in thyroid carcinoma using 68Ga-tilmanocept PET/CT
2021-002470-42Phase 3Completed
- Sponsor
- University Medical Center Utrecht
- Start
- Oct 2021
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of technetium tc 99m tilmanocept in thyroid cancer, sponsored by University Medical Center Utrecht. Primary endpoint: Number of sentinel lymph nodes determined on PET/CT. Started Oct 2021; status: completed.
02
Drugs
technetium tc 99m tilmanocept
03
Conditions
thyroid cancer
Beyond the preview
Go deeper on 2021-002470-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-002470-42.